All In Biotech

Drug Trial Radar · NCT01820325

Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer

A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology

Last checked: Nov 20, 2026Latest source record: Oct 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

6

Actual

Start

Sep 9, 2013

Primary completion

Jun 18, 2014

Study completion Jun 18, 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase Ib part of the study aimed to determine the maximum tolerated dose/recommended Phase II dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin and paclitaxel in patients with previously untreated metastatic squamous NSCLC. The purpose of the Phase II portion of the study was to assess the treatment effect of adding buparlisib versus buparlisib-matching placebo to every-three-week carboplatin and paclitaxel on progression free survival (PFS) in patients with previously untreated metastatic squamous NSCLC.

Conditions

  • Non-Small Cell Lunch Cancer

Interventions

  • BuparlisibDrug

  • Buparlisib placeboDrug

    Placebo + Carboplatin + Paclitaxel

  • CarboplatinDrug

  • PaclitaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Total Dose-limiting Toxicity (DLT) During Dose Escalation to Determine Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (21 days)
  2. Progression Free Survival (PFS) as measured using RECIST 1.1Time frame: Randomization, every 6 weeks to the date of first document progression for up to 3 years

Locations

7 sites in 5 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • Northwest Cancer Specialists Compass Oncology -BKM

    Portland, Oregon

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Naples, Italy

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.